Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue 1, 1996, Pages 23-30

  Holst, Jan ^a,b   Lindblad, Beugt ^a   Nordfang, Oie ^c   Østergaard, Per B ^c   Hedner, Ulla ^c  

^a LUND UNIVERSITY   (Sweden)

^b HELSINGBORG HOSPITAL   (Sweden)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Experimental thrombosis; Glycosylation; Low molecular weight heparin; Tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TINZAPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOSIS;

EID: 0030032907     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217184     Document Type: Article

References (25)

1. Warn-Cramer BJ. Rao LVM, Maki SL, Rapaport SI: Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VII-tissue factor: Evidence for a two step model of inhibition. Thromb Hae-most 1988;60:453-456.
2. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ. Mile-tich JP: The lipoprotein-associated coagulation inhibitor that inhibits the factor Vlla-tissue factor complex also inhibits factor Xa: Insights into its possible mechanism of action. Blood 1988;71:335-343.
3. Mann KG, Krishnaswamy S, Law-son JH: Surface-dependent hemostasis. Semin Hematol 1992;29: 213-226.
4. Broze GJ Jr: The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992;29:159-169.
5. Rapaport SI: The extrinsic pathway inhibitor, a regulator of the tissue factor-dependent blood coagulation. Thromb Haemost 1991;66:6-15.
6. Holst J. Lindblad B, Bergqvist D, Nordfang O, Gstergaard PB: Is EPI as antithrombotic agent comparable to LMWH?-A pilot double-dummy experimental study (abstract 912). Thromb Haemost 1991;6:951.
7. Holst J. Lindblad B, Bergqvist D, Nordfang O, Gstergaard PB. Petersen J. Nielsen G, Hedner U: Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPIi_i6i) in experimental venous thrombosis-A comparison with low molecular weight heparin. Thromb Haemost 1994;71:214-219.
8. Haskel EJ. Torr KC, Day KC, Palmier MO, Wun TC, Sobel BE, Abendschein DR: Prevention of reocclusion after thrombosis with recombinant lipoprotein associated coagulation inhibitor. Circulation 1991;84:821-827.
9. Spokas EG, Wun TC: Venous thrombosis produced in the vena cava of rabbits by vascular damage and stasis. J Pharmacol Toxicol Methods 1992;27:225-232.
10. Khouri RK, Koudsi B, Raiding F, Ornberg RL, Wun T-C: Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plast Surg 1993;30:398-404.
11. Girard TJ. Warren LA, Novotny WF, Likert KM, Brown SG, Mile-tich JP, Broze GJ Jr: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-520.
12. Bjork C, Bergqvist D, Esquivel CO, Nilsson B, Rudsvik Y: Effect of heparin, low molecular weight (LMW) heparin, and a heparin analogue on experimental venous thrombosis in the rabbit. Acta Chir Scand 1984; 150:629-633.
13. Petersen JGL, Meyn G, Rasmussen JS, Christiansen L, Petersen J. Bjorn SE, Jonassen I, Nordfang O: Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevi-siae. J Biol Chem 1993,268:13344-13351.
14. Sandset PM, Abildgaard U, Petter-sen M: A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987,47:389-400.
15. Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen M, Moeller KB, Meidahl-Pcdcrsen J. Beck TC, Norris K, Hedner U, Kie-sel W: Recombinant human extrinsic pathway inhibitor, production, isolation and characterization of its inhibitory activity on tissue factor initiated coagulation reactions. J Biol Chem 1990;265:16789-16793.
16. Matzsch T, Bergqvist D, Hedner U, Ostergaard PB: Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987;57:97-101.
17. Lindahl AK, Sandset PM, Abild-gaard U: The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1992,3:439-449.
18. Girard TJ. Brozc GJ Jr: Tissue factor pathway inhibitor. Methods En-zymol 1993;222:195-209.
19. Day K.C, Welsch DJ: Bacterial expression. purification and partial characterization of amino acids 94-155 of human tissue factor pathway inhibitor (TFPI) as an inhibitor of blood coagulation factor Xa. Thromb Res 1992;68:369-381.
20. Matthiasson SE: Low molecular weight heparin and dextran in thromboprophylaxis. Human and experimental studies; thesis, Lund 1994.
21. Warn-Cramer BJ. Maki SL. Rapa-port SI: A sulfated rabbit endothelial cell glycoprotein that inhibits factor Vlla/tissue factor is functionally and immunogenetically identical to rabbit extrinsic pathway inhibitor (EPI). Thromb Res 1991,61:515-527.
22. Belaaouaj A, Kuppuswamy MN, Birktoft JJ. Bajaj SP: Revised cDNA sequence of rabbit tissue factor pathway inhibitor. Thromb Res 1993;69:547-553.
23. Warn-Cramer BJ. Maki SL: Purification of tissue factor pathway inhibitor (TFPI) from rabbit plasma and characterization of its differences from TFPI isolated from human plasma. Thromb Res 1992;67: 367-383.
24. Bregengaard C, Nordfang O, 0ster-gaard P, Petersen JGL, Myen G, Di-ncss V, Svendsen O, Hedner U: Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993;70:454-457.
25. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U: The c-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991;30:10371-10376.